Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ATPC | Agape Atp | $3.74 | $1.72 | 85.15% | 709.3K | $2.0M | $1.72$128.25 |
| INKT | MiNK Therapeutics | $14.44 | $3.99 | 38.18% | 199.1K | $49M | $6.34$76.00 |
| ACXP | Acurx Pharmaceuticals | $2.61 | $0.66 | 33.51% | 16.2M | $5.0M | $1.33$21.00 |
| IXHL | Incannex Healthcare | $5.29 | $1.06 | 25.08% | 366.8K | $49M | $2.40$49.80 |
| AGCC | Agencia Comercial Spirits | $22.50 | $4.30 | 23.63% | 17.7K | $626M | $3.66$24.98 |
| MGNX | MacroGenics | $2.92 | $0.56 | 23.52% | 66.4K | $149M | $0.99$2.95 |
| GITS | Global Interactive Technologies | $2.77 | $0.51 | 22.51% | 63K | $8.3M | $0.66$7.09 |
| ZVRA | Zevra Therapeutics | $11.09 | $1.97 | 21.60% | 144.2K | $513M | $6.19$13.16 |
| TTEC | TTEC Holdings | $3.01 | $0.52 | 20.88% | 896.5K | $121M | $1.98$5.60 |
| RVNL | GraniteShares ETF Trust - GraniteShares 2x Long Rivn Daily ETF | $39.08 | $6.20 | 18.86% | 40.1K | - | $24.49$75.17 |
| LFMD | LifeMD | $3.70 | $0.58 | 18.43% | 3.1M | $150M | $2.56$15.84 |
| TENX | Tenax Therapeutics | $12.97 | $1.95 | 17.65% | 795.2K | $69M | $4.63$18.38 |
| CAPR | Capricor Therapeutics | $35.99 | $5.36 | 17.50% | 2.3M | $1.7B | $4.30$40.37 |
| EDIT | Editas Medicine | $2.72 | $0.40 | 17.03% | 80.8K | $226M | $0.91$4.54 |
| FGI | Fgi Industries | $3.95 | $0.54 | 15.90% | 5.9K | $6.5M | $2.28$12.62 |
| AXTI | AXT | $44.55 | $5.99 | 15.53% | 342.2K | $2.1B | $1.13$47.03 |
| ALEC | Alector | $2.53 | $0.34 | 15.30% | 756.3K | $242M | $0.87$3.40 |
| SAVA | Cassava Sciences | $2.43 | $0.31 | 14.62% | 23K | $102M | $1.15$4.98 |
| VYGR | Voyager Therapeutics | $4.71 | $0.60 | 14.60% | 410.8K | $229M | $2.65$5.55 |
| QVCGA | Qvc Group | $3.57 | $0.44 | 14.21% | 45.6K | $25M | $2.27$15.98 |
| TXXD | Listed Funds Trust - 21Shares 2x Long Dogecoin ETF | $6.99 | $0.87 | 14.15% | 26.9K | - | $5.94$27.68 |
| CRMU | Themes ETF Trust - Leverage Shares 2x Long Crml Daily ETF | $8.58 | $0.98 | 12.90% | 14.8K | - | $6.52$15.25 |
| PIII | P3 Health Partners | $3.24 | $0.36 | 12.31% | 179.3K | $9.5M | $1.52$11.30 |
| TBMC | Trailblazer Merger I | $11.15 | $1.20 | 12.07% | 95.2K | $24M | $7.77$14.91 |
| PEPG | PepGen | $6.24 | $0.67 | 12.03% | 170.2K | $385M | $0.88$7.80 |
| GEMG | Themes ETF Trust - Leverage Shares 2x Long Gemi Daily ETF | $2.66 | $0.13 | 4.99% | 35.1K | - | $1.13$17.73 |
| APPX | Investment Managers Series Trust II - Tradr 2x Long App Daily ETF | $44.30 | -$3.85 | -8.00% | 194.8K | - | $20.21$157.62 |
Related Articles
Featured Article
Here's Why This Biotechnology Skyrocketed by 439% in December
Lee Samaha|Jan 9, 2026
A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment.
1 Small-Cap Stock I'd Buy Before GLBE in 2026
Marc Guberti|Jan 8, 2026
Global-E Online is a small company trying to carve out a niche in the competitive e-commerce space, while AXT is a small semiconductor player that already has a lead in an emerging opportunity.
Can This Beaten-Down Stock Bounce Back?
Prosper Junior Bakiny|Aug 12, 2025
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
2 Beaten-Down Stocks to Avoid
Prosper Junior Bakiny|Jun 27, 2025
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Eric Volkman|May 9, 2024
The company has great potential if and when it enters the commercial stage.
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
Alex Carchidi|Mar 7, 2024
The company now has a chance to get its lead program out the door a bit sooner.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
Prosper Junior Bakiny|Mar 4, 2024
The biotech has bounced back some in the past year.
Is There Any Hope for Cassava Sciences Stock?
Alex Carchidi|Feb 3, 2024
Battered by controversy, this company will need to show real results to prosper.
2 Under-the-Radar Stocks With Incredible Upside Potential
Prosper Junior Bakiny|Jan 28, 2024
It's also important to consider their downsides.
